Wall Street analysts expect that AxoGen, Inc Common Stock (NASDAQ:AXGN) will announce ($0.05) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for AxoGen, Inc Common Stock’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.07). AxoGen, Inc Common Stock reported earnings per share of ($0.06) during the same quarter last year, which would indicate a positive year over year growth rate of 16.7%. The company is scheduled to issue its next quarterly earnings report on Wednesday, November 7th.
On average, analysts expect that AxoGen, Inc Common Stock will report full-year earnings of ($0.27) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.22). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.16) to ($0.07). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover AxoGen, Inc Common Stock.
AxoGen, Inc Common Stock (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The firm had revenue of $20.58 million during the quarter, compared to the consensus estimate of $21.25 million. AxoGen, Inc Common Stock had a negative net margin of 24.96% and a negative return on equity of 26.50%. The business’s revenue was up 35.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.04) earnings per share.
Several analysts recently weighed in on AXGN shares. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective (up from $37.00) on shares of AxoGen, Inc Common Stock in a report on Tuesday, May 1st. JMP Securities lifted their price objective on AxoGen, Inc Common Stock from $34.00 to $43.00 and gave the company a “market outperform” rating in a report on Tuesday, May 1st. ValuEngine upgraded AxoGen, Inc Common Stock from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Leerink Swann restated an “outperform” rating and issued a $70.00 price objective on shares of AxoGen, Inc Common Stock in a report on Tuesday, June 26th. Finally, BidaskClub downgraded AxoGen, Inc Common Stock from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. AxoGen, Inc Common Stock currently has a consensus rating of “Buy” and an average price target of $41.29.
Shares of AXGN stock traded down $0.50 on Wednesday, hitting $39.40. The stock had a trading volume of 394,142 shares, compared to its average volume of 640,349. The company has a market capitalization of $1.45 billion, a P/E ratio of -127.10 and a beta of 0.01. AxoGen, Inc Common Stock has a one year low of $15.35 and a one year high of $56.85.
In other news, Director Amy Mcbride Wendell acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average cost of $36.89 per share, for a total transaction of $184,450.00. Following the completion of the acquisition, the director now directly owns 18,333 shares of the company’s stock, valued at approximately $676,304.37. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.86% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. raised its holdings in AxoGen, Inc Common Stock by 844.4% in the second quarter. Meeder Asset Management Inc. now owns 2,427 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 2,170 shares in the last quarter. Mckinley Capital Management LLC Delaware bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $156,000. Bank of Montreal Can bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $180,000. Jane Street Group LLC bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $201,000. Finally, Quantitative Systematic Strategies LLC bought a new position in AxoGen, Inc Common Stock in the second quarter worth about $207,000. Institutional investors and hedge funds own 81.02% of the company’s stock.
About AxoGen, Inc Common Stock
AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
See Also: Leveraged Buyout (LBO) Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.